Patents by Inventor Tsung-Cheng Hu

Tsung-Cheng Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10703728
    Abstract: In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe for preparing the novel crystalline form of olaparib. The process includes forming a solution comprising crude olaparib and an organic solvent; adding the solution to an anti-solvent to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form III of olaparib.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 7, 2020
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang, Yung-Hung Chang, Kuan-Hsun Wang
  • Patent number: 10435395
    Abstract: Crystalline form S1 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 10.7±0.2, 16.2±0.2, 19.9±0.2, 22.1±0.2, 24.7±0.2, and 25.9±0.2 degrees two-theta, crystalline form S2 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 16.4±0.2, 24.9±0.2, and 26.2±0.2 degrees two-theta, and processes of making thereof are provided.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 8, 2019
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, YuanChang Huang, Ming-Chih Wu
  • Publication number: 20190300512
    Abstract: Crystalline form S1 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 10.7±0.2, 16.2±0.2, 19.9±0.2, 22.1±0.2, 24.7±0.2, and 25.9±0.2 degrees two-theta, crystalline form S2 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 16.4±0.2, 24.9±0.2, and 26.2±0.2 degrees two-theta, and processes of making thereof are provided.
    Type: Application
    Filed: March 8, 2019
    Publication date: October 3, 2019
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, YuanChang Huang, Ming-Chih Wu
  • Patent number: 10138211
    Abstract: In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 27, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang
  • Publication number: 20180050991
    Abstract: In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.
    Type: Application
    Filed: October 27, 2017
    Publication date: February 22, 2018
    Inventors: Wen-Wei LIN, Tsung-Cheng Hu, Yuan-Chang Huang
  • Patent number: 9765026
    Abstract: The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: September 19, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Hsiao-ping Fang, Wei-Shuo Lo, Kuan Hsun Wang, Yu-Sheng Lin, Tsung-Cheng Hu, YuanChang Huang
  • Publication number: 20170260186
    Abstract: A process for preparing an amorphous form of idelalisib comprises: (a) forming a first solution of idelalisib in a solvent; (b) adding the first solution obtained in step (a) into water to form a second solution; (c) optionally cooling the second solution obtained in step (b) and; (d) isolating the optionally cooled second solution from step (c) to provide the amorphous form of idelalisib. Mild reaction conditions are used in this process. The amorphous form of idelalisib prepared by this process is stable and does not transfer to other crystalline forms easily. This process is suitable for large scale manufacture of idelalisib at a high yield.
    Type: Application
    Filed: March 1, 2017
    Publication date: September 14, 2017
    Inventors: Tsung-Cheng Hu, Wei-Shuo Lo, Kuan-Hsun Wang, Wan-Yin Cheng
  • Publication number: 20170204067
    Abstract: In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 20, 2017
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang
  • Publication number: 20170057916
    Abstract: The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.
    Type: Application
    Filed: August 24, 2016
    Publication date: March 2, 2017
    Inventors: Hsiao-ping FANG, Wei-Shuo LO, Kuan Hsun WANG, Yu-Sheng LIN, Tsung-Cheng HU, YuanChang HUANG
  • Patent number: 8481728
    Abstract: A process of making entecavir comprising converting a compound of formula (M5) to entecavir, wherein the two PGs on the formula (M5) are taken together to form an optionally substituted six- or seven-member cyclic ring.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: July 9, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Tsung-Cheng Hu, Hung-Tsung Huang
  • Patent number: 8013158
    Abstract: Novel crystalline forms of topotecan hydrochloride and processes of making the same are disclosed.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: September 6, 2011
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Tsung-Cheng Hu, Shu-Ping Chen, Piin-Jye Harn, Chia-Lin Charlene Shieh
  • Publication number: 20110201809
    Abstract: A process of making entecavir comprising converting a compound of formula (M5) to entecavir, wherein the two PGs on the formula (M5) are taken together to form an optionally substituted six- or seven-member cyclic ring.
    Type: Application
    Filed: February 15, 2011
    Publication date: August 18, 2011
    Inventors: Tsung-Cheng Hu, Hung-Tsung Huang
  • Patent number: 7977483
    Abstract: A process of making topotecan or a pharmaceutically acceptable salt thereof comprising reacting an iminium salt with 10-hydroxy-camptothecin.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: July 12, 2011
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Tsung-Cheng Hu, Piin-Jye Harn
  • Publication number: 20110021769
    Abstract: A process for making a capecitabine or its derivative comprising (a) reacting a compound of the formula (II): wherein each of R1 and R2 independently represents a hydroxyl protecting group, with an acylating agent of formula (III): X—C(?O)—R3, wherein X is an acyl activating group in an organic solvent to produce an acylated compound; (b) deprotecting the acylated compound to obtain the compound of formula (I); and (c) purifying the compound of formula (I) with a solvent.
    Type: Application
    Filed: July 21, 2010
    Publication date: January 27, 2011
    Inventors: Tsung-Cheng Hu, Hong-Tsung Huang
  • Patent number: 7629469
    Abstract: A new compound of formula (IV) R represents a protecting group which is removable by hydrogenation, and use thereof as an intermediate for preparing paliperidone.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: December 8, 2009
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Tsung-Cheng Hu, Hsiao-ping Fang, Hong-Tsung Huang
  • Publication number: 20090221826
    Abstract: A process of making topotecan or a pharmaceutically acceptable salt thereof comprising reacting an iminium salt with 10-hydroxy-camptothecin.
    Type: Application
    Filed: April 9, 2008
    Publication date: September 3, 2009
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Tsung-Cheng Hu, Piin-Jye Harn
  • Publication number: 20090182150
    Abstract: A new compound of formula (IV) R represents a protecting group which is removable by hydrogenation, and use thereof as an intermediate for preparing paliperidone.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 16, 2009
    Inventors: Tsung-Cheng Hu, Hsiao-ping Fang, Hong-Tsung Huang
  • Publication number: 20090118248
    Abstract: The invention relates to a novel multi step process of making compounds of Formula I: wherein R1 is an alkoxy group and R2 is an optionally substituted, N-attached heteroaryl. The hydrogen at the 5-position can be ? or ? isomer, preferably ?. Preferably the compound of Formula I is 17? isomer. The invention also relates to novel 3?-hydroxy-3?-substituted-17-substituted steroid compounds having GABAA receptor modulating activity, pharmaceutical compositions comprising these compounds, and the use of these compounds in a method of modulating brain excitability.
    Type: Application
    Filed: April 22, 2005
    Publication date: May 7, 2009
    Applicant: Euro-Celtique S.A.
    Inventors: Ping W. Chang, Ning Zhong, Xinping Fang, Shao-Kun Pang, Chi-Nung Hsiao, Tsung-Cheng Hu
  • Publication number: 20080269493
    Abstract: Novel crystalline forms of topotecan hydrochloride and processes of making the same are disclosed.
    Type: Application
    Filed: April 14, 2008
    Publication date: October 30, 2008
    Applicant: ScinoPharm Taiwan Ltd.
    Inventors: Tsung-Cheng Hu, Piin-Jye Harn, Shu-Ping Chen, Chia-Lin Charlene Shieh